Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares fell 2.6% on Thursday . The company traded as low as $15.43 and last traded at $15.43, with a volume of 100,576 shares trading hands. The stock had previously closed at $15.84.

A number of research firms have recently weighed in on ADMS. Mizuho lifted their price objective on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, April 28th. Noble Financial began coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They set a “buy” rating and a $25.00 price objective on the stock. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $33.60.

The stock’s market cap is $335.00 million. The stock has a 50 day moving average of $16.29 and a 200 day moving average of $17.19.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.11. Equities analysts predict that Adamas Pharmaceuticals Inc. will post ($3.09) earnings per share for the current fiscal year.

In other news, SVP Natalie Mcclure sold 36,000 shares of the stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $18.50, for a total value of $666,000.00. Following the transaction, the senior vice president now directly owns 21,006 shares of the company’s stock, valued at $388,611. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several hedge funds and institutional investors have recently made changes to their positions in ADMS. EAM Investors LLC purchased a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth $4,006,000. Tocqueville Asset Management L.P. raised its stake in Adamas Pharmaceuticals by 60.0% in the fourth quarter. Tocqueville Asset Management L.P. now owns 40,000 shares of the specialty pharmaceutical company’s stock valued at $1,133,000 after buying an additional 15,000 shares during the period. Strs Ohio raised its stake in Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock valued at $1,127,000 after buying an additional 12,700 shares during the period. Finally, Russell Frank Co raised its stake in Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock valued at $2,395,000 after buying an additional 45,652 shares during the period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.